BidaskClub downgraded shares of DaVita HealthCare Partners Inc. (NYSE:DVA) from a sell rating to a strong sell rating in a research note released on Saturday morning.

DVA has been the topic of several other reports. Zacks Investment Research upgraded DaVita HealthCare Partners from a hold rating to a buy rating and set a $77.00 price objective on the stock in a research note on Tuesday, April 18th. Goldman Sachs Group, Inc. (The) reiterated a sell rating and issued a $62.00 price objective on shares of DaVita HealthCare Partners in a research note on Thursday, May 25th. Jefferies Group LLC set a $70.00 price objective on DaVita HealthCare Partners and gave the company a buy rating in a research note on Friday, May 26th. Finally, TheStreet lowered DaVita HealthCare Partners from a b rating to a c+ rating in a research note on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the stock. DaVita HealthCare Partners presently has a consensus rating of Hold and an average target price of $69.50.

Shares of DaVita HealthCare Partners (NYSE DVA) opened at 56.85 on Friday. DaVita HealthCare Partners has a one year low of $54.50 and a one year high of $76.97. The company has a 50 day moving average price of $64.78 and a 200 day moving average price of $66.07. The company has a market cap of $10.87 billion, a P/E ratio of 8.66 and a beta of 0.89.

DaVita HealthCare Partners (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 1st. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.02. DaVita HealthCare Partners had a return on equity of 14.02% and a net margin of 8.68%. The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period in the prior year, the company posted $1.01 EPS. The company’s revenue was up 4.3% compared to the same quarter last year. Equities research analysts expect that DaVita HealthCare Partners will post $3.54 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “DaVita HealthCare Partners Inc. (DVA) Downgraded by BidaskClub” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/08/davita-healthcare-partners-inc-dva-downgraded-by-bidaskclub.html.

In other news, CEO Javier Rodriguez sold 1,294 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $66.21, for a total value of $85,675.74. Following the transaction, the chief executive officer now directly owns 99,111 shares of the company’s stock, valued at approximately $6,562,139.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.00% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in DVA. Vanguard Group Inc. increased its position in shares of DaVita HealthCare Partners by 2.2% in the first quarter. Vanguard Group Inc. now owns 15,080,919 shares of the company’s stock valued at $1,025,050,000 after buying an additional 331,482 shares during the last quarter. BlackRock Inc. increased its position in shares of DaVita HealthCare Partners by 2,315.8% in the first quarter. BlackRock Inc. now owns 12,892,477 shares of the company’s stock valued at $876,303,000 after buying an additional 12,358,806 shares during the last quarter. State Street Corp increased its position in shares of DaVita HealthCare Partners by 0.5% in the first quarter. State Street Corp now owns 7,533,514 shares of the company’s stock valued at $512,049,000 after buying an additional 38,416 shares during the last quarter. Boston Partners increased its position in shares of DaVita HealthCare Partners by 4.2% in the first quarter. Boston Partners now owns 6,812,176 shares of the company’s stock valued at $463,024,000 after buying an additional 276,662 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of DaVita HealthCare Partners by 11.3% in the first quarter. Bank of New York Mellon Corp now owns 3,129,111 shares of the company’s stock valued at $212,686,000 after buying an additional 317,775 shares during the last quarter. 84.32% of the stock is currently owned by institutional investors and hedge funds.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.